[go: up one dir, main page]

ES2094837T3 - Metodo para inhibir la toxicidad pulmonar por oxigeno. - Google Patents

Metodo para inhibir la toxicidad pulmonar por oxigeno.

Info

Publication number
ES2094837T3
ES2094837T3 ES92105035T ES92105035T ES2094837T3 ES 2094837 T3 ES2094837 T3 ES 2094837T3 ES 92105035 T ES92105035 T ES 92105035T ES 92105035 T ES92105035 T ES 92105035T ES 2094837 T3 ES2094837 T3 ES 2094837T3
Authority
ES
Spain
Prior art keywords
oxygen toxicity
inhibiting pulmonary
pulmonary oxygen
inhibiting
toxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92105035T
Other languages
English (en)
Inventor
Craig D Wegner
L Gordon Letts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2094837T3 publication Critical patent/ES2094837T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

METODO PARA INHIBIR LA TOXICIDAD DEL OXIGENO PULMONAR. UN METODO PARA INHIBIR LA TOXICIDAD DEL OXIGENO PULMONAR EN UN PACIENTE QUE NECESITE NIVELES ELEVADOS DE OXIGENO INHALADO, MEDIANTE LA ADMINISTRACION PROFILATICA DE CIERTAS MOLECULAS Y ANTICUERPOS DE ADHERENCIA AL MISMO.
ES92105035T 1991-04-03 1992-03-24 Metodo para inhibir la toxicidad pulmonar por oxigeno. Expired - Lifetime ES2094837T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67987091A 1991-04-03 1991-04-03

Publications (1)

Publication Number Publication Date
ES2094837T3 true ES2094837T3 (es) 1997-02-01

Family

ID=24728710

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92105035T Expired - Lifetime ES2094837T3 (es) 1991-04-03 1992-03-24 Metodo para inhibir la toxicidad pulmonar por oxigeno.

Country Status (12)

Country Link
US (1) US5310551A (es)
EP (1) EP0507187B1 (es)
JP (1) JP3228548B2 (es)
AT (1) ATE145827T1 (es)
AU (1) AU655459B2 (es)
CA (1) CA2064604C (es)
DE (1) DE69215568T2 (es)
DK (1) DK0507187T3 (es)
ES (1) ES2094837T3 (es)
GR (1) GR3022578T3 (es)
NZ (1) NZ242192A (es)
ZA (1) ZA922408B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
US20190290623A1 (en) * 2018-03-26 2019-09-26 The Unites States of America Represented by the Secretary of Navy Use of tiotropium bromide to prevent pulmonary oxygen toxicity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
DK0387701T3 (da) * 1989-03-09 1992-12-07 Boehringer Ingelheim Pharma Anvendelse af intercellulære adhæsionsmolekyler samt deres bindende ligander ved behandling af astma

Also Published As

Publication number Publication date
EP0507187B1 (en) 1996-12-04
AU1398692A (en) 1992-10-08
EP0507187A1 (en) 1992-10-07
DE69215568D1 (de) 1997-01-16
ZA922408B (en) 1992-12-30
DE69215568T2 (de) 1997-05-15
CA2064604A1 (en) 1992-10-04
HK1003106A1 (en) 1998-10-09
DK0507187T3 (da) 1997-04-07
JP3228548B2 (ja) 2001-11-12
GR3022578T3 (en) 1997-05-31
NZ242192A (en) 1997-06-24
AU655459B2 (en) 1994-12-22
US5310551A (en) 1994-05-10
JPH05255103A (ja) 1993-10-05
CA2064604C (en) 2007-07-10
ATE145827T1 (de) 1996-12-15

Similar Documents

Publication Publication Date Title
DE3868127D1 (de) F-serien-prostaglandine.
NO2008010I1 (no) Kombinasjon av efavirenz, emtricitabin og tenofovirdisoproks: 1 eller salter derav
DE69232480D1 (de) Beatmungsgerät zur Erzeugung von kontinuierlichem positiven Atemwegdruck (CPAP)
ATE285241T1 (de) Pharmazeutische zubereitungen, enthaltend salze von hyaluronsäure und lokalanästhetika
RS49577B (sr) Formulacije analoga insulina
DK0509019T3 (da) Behandling af humane retrovirale infektioner med 2',3'-dideoxyinosin
YU59092A (sh) Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja
DK617189A (da) Anvendelse af bis(3,5-di-t-butyl-4-hydroxy-phenylthio)-methan til fremstilling af et laegemiddel mod atherosclerose og hypercholesterolaemi
TR199701654T1 (xx) 4-Fenilaminotiyazol t�revleri.
ATE234615T1 (de) Verwendung von acetylcystein zur herstellung eines arzneimittels zur behandlung von chronischen geschwüren
ATE221083T1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
TR199901772T2 (es)
DE69401972D1 (de) Feste Arzneimitteldosierungsform und Methode zur Verminderung des Abriebs
ES2094837T3 (es) Metodo para inhibir la toxicidad pulmonar por oxigeno.
DE59100216D1 (de) Zerlegbare spurtraegerbruecke mit zwischen den spurtraegern angeordnetem vorbautraeger.
DK0476113T3 (da) Lægemiddel til behandling af hyperlipidæmi og/eller atherosklerose
AU7777794A (en) Melatonin derivatives for use in treating sleep disorders
ATE121420T1 (de) Verfahren zur herstellung von 3-(l-pyroglutamyl)- l-thiazolidin-4-carbonsäure-derivaten.
FI94043B (fi) Menetelmä hajuttoman ja steriilin pakkauksen aikaansaamiseksi ja menetelmällä aikaansaatu steriloitava tuotepakkaus
DE59203456D1 (de) Flüchtige Inhalationsnarkotika enthaltende Liposomen, ihre Herstellung und Verwendung.
DE59309355D1 (de) Neue Phospholipidderivate
EP0401262A4 (en) 24r-scymnol, and preparation and use thereof
SE8903764D0 (sv) Lung protection agents
ITMI913466A0 (it) Procedimento per la depurazione dell'1.1.1-trifluoro-2-fluoroetano e dell'1.1.1-trifuoro-2,2-diocloroetano
ATE148991T1 (de) Nicotinamid-adenin-dinukleodid enthaltendes antidepressionsmittel

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 507187

Country of ref document: ES